MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2026.116729

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2026

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.

Robert Marie, Kotecki Nuria, Gomez-Roca Carlos, Massard Christophe, Postel-Vinay Sophie, Raimbourg Judith, Brandao Mariana, Korakis Iphigénie, Rouge Thibaut de la Motte, Comis Silvia, Imadalou Karima, Chevalier Caroline, Cordonnier Laurie, Josse Constant, Teppaz Géraldine, Seité Margaux, Durand Justine, Thepenier Virginie, Mary Caroline, Gauttier Vanessa, Derame Mylène, Morello Aurore, Poirier Nicolas, Cassier Philippe Alexandre

СтатьяКлиническое исследование I фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

OSE-279 is a high affinity humanized monoclonal bivalent antibody against PD-1 with potent antitumor activity in vivo in syngeneic non-clinical models.

METHODS

This phase I study assessed the safety, pharmacokinetics, pharmacodynamics and antitumor activity of OSE-279 in advanced solid tumours.

RESULTS

Twenty patients received OSE-279 intravenously at 100 mg q3w (n = 2), 300 mg q3w (n = 7) and 600 mg q6w (n = 11). Median age was 61.5 (range 3-81) years, 50% were female, median number of prior metastatic lines was 2 (range 1-6). Most frequent tumour types were soft tissue sarcoma (n = 4) and anal squamous cell carcinoma (n = 3). OSE-279 monotherapy was safe. Two recommended phase 2 doses were established: 300 mg q3w and 600 mg q6w. The most common (≥10%) related TEAEs were diarrhoea, dry mouth, pruritus, chills, fatigue, headache, dysgeusia and hyperthyroidism. OSE-279 PK exhibited linear dose proportionality and mean receptor occupancy was maintained above 80% in all tested doses. There were 1 CR at 300 mg q3w, 4 PRs at 600 mg q6w and 7 SD with response duration ranging from 6.8 to 18.4 months.

CONCLUSION

OSE-279 monotherapy was well tolerated with durable responses in patients with advanced solid tumours. The trial is continuing with OSE-279 combined with OSE2101, a therapeutic cancer vaccine in 1st line HLA-A2 positive PD-L1 ≥ 50% NSCLC. CLINICAL TRIAL REGISTRATION (NCT NUMBER: NCT05751798).

Для цитирования: Robert Marie, Kotecki Nuria, Gomez-Roca Carlos, Massard Christophe, Postel-Vinay Sophie, Raimbourg Judith, Brandao Mariana, Korakis Iphigénie, Rouge Thibaut de la Motte, Comis Silvia, Imadalou Karima, Chevalier Caroline, Cordonnier Laurie, Josse Constant, Teppaz Géraldine, Seité Margaux, Durand Justine, Thepenier Virginie, Mary Caroline, Gauttier Vanessa, Derame Mylène, Morello Aurore, Poirier Nicolas, Cassier Philippe Alexandre. A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.. European journal of cancer (Oxford, England : 1990). 2026. DOI: 10.1016/j.ejca.2026.116729.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.